Synact Pharma intensifies partnership discussions
![Photo: Synact Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13538351.ece/ALTERNATES/schema-16_9/doc7iqxdhj60px1b4gunmo.jpg)
Synact Pharma is going in with good cards in a hunt for potential partners. Last week, the biotech firm could reveal promising results from a smaller phase IIa study with its drug candidate, AP1189, against arthritis.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.